Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Navigating Cisplatin Shortages and the Need for Legislation

August 24, 2023
By Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC
Commentary
Video

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, believes that national legislation can help to resolve the United States’ current dearth of cisplatin, as well as prevent future problems.

Several factors have contributed to the ongoing cisplatin shortage, ranging from manufacturing issues, supply chain difficulties, and even prioritizing the production of other branded cancer therapies over generics, according to Kirollos Hanna, PharmD, BCPS, BCOP, FACCC.

During an interview with CancerNetwork®, Hanna, director of Minnesota Oncology Pharmacy Services, and assistant professor of Pharmacy at the Mayo Clinic provided insight into why the shortages have occurred but also hypothesized potential solutions. In particular, he stated that regulatory authorities can learn from the current shortage and that legislation may play a role in avoiding future shortages.

Transcript:

This cisplatin shortage stemmed from [a quality control issue with] one of the largest manufacturers that make about 70% to 80% of the cisplatin in the country. The FDA had to shut down that plant, and [the manufacturer is] working with them. All of a sudden, [for] other generic manufacturers that were generally responsible for making about 20% of allocations for the country, the ask is much higher, and they can’t produce accordingly. We have seen numerous things that have led to shortages, sometimes pandemic related, sometimes pre-pandemic. We’ve been dealing with shortages for years now.

What I find interesting is if you look at [drugs like] Keytruda [pembrolizumab], Opdivo [nivolumab], or Darzalex [daratumumab], if you look at these branded therapeutics—these monoclonal antibodies where so much money is invested from these larger pharmaceutical companies—we will never find a shortage of these drugs. Why is it that these critical therapeutics that in many areas are tied to curative intent regimens [have shortages]? Why do we not invest in those plants, [and] organizations to alleviate the situation from ever happening?

Why don’t we partner with different manufacturers outside of the United States, similar to what we did with China to [help alleviate] the cisplatin shortage? Why do we wait until it gets so critical? For something of this magnitude, for there to be a true resolution, there needs to be something that comes down from legislation that is national and governs all. Sometimes because of the cheap cost of generic therapeutics, a lot of time and money, and effort aren’t invested in that because the ROI [return on investment], isn’t there, as you see with your big, branded products.

That’s where I do think that needs to happen from a national level for this situation to resolve now. As healthcare providers, the number of times we’ve seen this should have people think a little bit differently about shortages.

Recent Videos
Physical therapists may play a key role in patient care before, during, and after treatment for cancer, according to Alison Ankiewicz, PT, DPT.
Prophylactic steroid or tocilizumab use may help in preventing CRS in patients undergoing treatment with bispecific antibodies for multiple myeloma.
Recommending counseling sessions may help patients with cancer navigate sexual health and emotional issues during their cancer treatment.
Related Content
Advertisement

Twice-daily radiotherapy prolongs survival vs once-daily radiation among those with LS-SCLC, even with the incorporation of immunotherapy.

Unraveling The Benefits of Twice-Daily Chemoradiotherapy in LS-SCLC

Russ Conroy
October 3rd 2025
Article

Twice-daily radiotherapy prolongs survival vs once-daily radiation among those with LS-SCLC, even with the incorporation of immunotherapy.


Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.


Acknowledging Mortality and Death in Cancer Care

Acknowledging Mortality and Death in Cancer Care

Ariana Pelosci
September 29th 2025
Article

In the oncology setting, having discussions about mortality and death may be daunting for patients, but is vital and inevitable.


How to Discuss Death: A Conversation of Mortality in Cancer Care

How to Discuss Death: A Conversation of Mortality in Cancer Care

Daniel C. McFarland, DO;William Breitbart, MD
September 22nd 2025
Podcast

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.


Managing AEs with Gemcitabine Intravesical System in NMIBC

Managing AEs with Gemcitabine Intravesical System in NMIBC

Gary Steinberg, MD
September 20th 2025
Article

Gary Steinberg, MD, compared the AE profile of the gemcitabine intravesical system for BCG-unresponsive NMIBC with other intravesical therapies.


Data from the phase 3 3475A-D77 trial support the FDA approval of subcutaneous pembrolizumab across different pediatric and adult solid tumor indications.

FDA Approves SC Pembrolizumab Formulation in Solid Tumors

Tim Cortese
September 19th 2025
Article

Data from the phase 3 3475A-D77 trial support the FDA approval of subcutaneous pembrolizumab across different pediatric and adult solid tumor indications.

Related Content
Advertisement

Twice-daily radiotherapy prolongs survival vs once-daily radiation among those with LS-SCLC, even with the incorporation of immunotherapy.

Unraveling The Benefits of Twice-Daily Chemoradiotherapy in LS-SCLC

Russ Conroy
October 3rd 2025
Article

Twice-daily radiotherapy prolongs survival vs once-daily radiation among those with LS-SCLC, even with the incorporation of immunotherapy.


Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.


Acknowledging Mortality and Death in Cancer Care

Acknowledging Mortality and Death in Cancer Care

Ariana Pelosci
September 29th 2025
Article

In the oncology setting, having discussions about mortality and death may be daunting for patients, but is vital and inevitable.


How to Discuss Death: A Conversation of Mortality in Cancer Care

How to Discuss Death: A Conversation of Mortality in Cancer Care

Daniel C. McFarland, DO;William Breitbart, MD
September 22nd 2025
Podcast

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.


Managing AEs with Gemcitabine Intravesical System in NMIBC

Managing AEs with Gemcitabine Intravesical System in NMIBC

Gary Steinberg, MD
September 20th 2025
Article

Gary Steinberg, MD, compared the AE profile of the gemcitabine intravesical system for BCG-unresponsive NMIBC with other intravesical therapies.


Data from the phase 3 3475A-D77 trial support the FDA approval of subcutaneous pembrolizumab across different pediatric and adult solid tumor indications.

FDA Approves SC Pembrolizumab Formulation in Solid Tumors

Tim Cortese
September 19th 2025
Article

Data from the phase 3 3475A-D77 trial support the FDA approval of subcutaneous pembrolizumab across different pediatric and adult solid tumor indications.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.